Latin American device regulators moved on convergence, channel integrity, and post-market controls this week. Chile studied Brazil’s full device-lifecycle model, Colombia escalated enforcement against injectable implants sold through unauthorized digital channels, and Peru issued new risk-control instructions for products used to clean reusable devices.
Brazil · Chile · Colombia · Peru
ANVISA hosted representatives from Chile’s Instituto de Salud Pública from July 6 through July 10 for a technical exchange covering company authorization, sanitary registration, Good Manufacturing Practices certification, imports, inspections, and post-market surveillance. The official ANVISA account describes the program as part of a broader effort to strengthen regulatory convergence across Latin America.
Why it matters: This is not a new reliance pathway or filing rule. It is nevertheless a meaningful signal that Brazil’s integrated device-control architecture is becoming a regional reference point. Manufacturers should expect documentation on establishment authorization, GMP status, import controls, and post-market responsibilities to become increasingly connected rather than treated as separate filing exercises.
Chile’s delegation reviewed how ANVISA coordinates each stage of the device regulatory cycle, including registration, inspections, imports, monitoring, and field surveillance. According to ANVISA’s summary of the exchange, the visit was designed to support institutional capacity and the exchange of regulatory practices.
What to focus on: Sponsors should not assume that Chile will copy Brazil’s requirements. The practical implication is directional: Chile is studying a more integrated lifecycle model while expanding its own device oversight. Companies entering Chile should maintain a single evidence package that aligns product classification, manufacturer controls, importer responsibilities, technical documentation, and post-market procedures.
INVIMA issued Alert 208-2026 after authorized importers identified injectable implants and hyaluronic-acid products being marketed through unauthorized e-commerce platforms, social networks, and messaging channels. The official INVIMA alert names products associated with Sardenya Colombia, Merz Colombia, Global Skin, and AbbVie and directs providers to verify registrations, authorized importers, labeling, lot information, and supply-chain traceability before use.
Bottom line: A valid sanitary registration is not sufficient if the commercial channel cannot demonstrate authorized sourcing and traceability. Device manufacturers and registration holders should monitor online sales, document approved distributors, maintain implant-card traceability, and ensure Spanish labeling identifies the authorized importer and registration number.
DIGEMID’s Alert 077-2026 addresses risks associated with enzymatic detergents used to clean medical, dental, and surgical devices. The official DIGEMID alert reports 82 suspected adverse-incident notifications between 2016 and 2026 and instructs registration holders to report incidents, train users, and communicate or implement manufacturer-directed field safety actions when required.
Why it matters: Post-market responsibility can extend beyond the device itself to cleaning agents and reprocessing instructions that affect safe use. Registration holders should confirm that local training, instructions for use, dilution requirements, contact times, ventilation controls, and incident-reporting procedures remain aligned.
Need help navigating LATAM regulatory pathways? bioaccess® provides market access services with U.S. regulatory anchoring and Latin American execution — from device registration to commercial launch. Visit bioaccessla.com/market-access.
← All LATAM Regulatory Dispatch editions · Contact bioaccess®